[Form 4] Century Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brent Pfeiffenberger, President and CEO and a director of Century Therapeutics, Inc. (IPSC), received a grant of 1,587,614 restricted stock units (RSUs) on 08/14/2025. Each RSU converts into one share of common stock and will settle in shares on vesting. The RSUs vest 50% on August 14, 2027 and the remaining 50% on August 14, 2028, each tranche conditioned on continued service through the vesting date. The reported transaction shows an acquisition at a reported price of $0 and indicates 3,269,397 shares beneficially owned by the reporting person after the transaction. The Form 4 was filed for this single reporting person and signed by an attorney-in-fact on 08/18/2025.

Insights

Financial Analyst

TL;DR: Large RSU grant aligns CEO incentives with shareholder value but increases share-based compensation expense.

The Form 4 documents a sizeable equity award of 1,587,614 RSUs to the reporting person, vesting in two equal tranches over two and three years. From a compensation perspective, such an award is a standard tool to retain and incentivize senior management by tying pay to future service and potential share appreciation. The reported post-transaction beneficial ownership of 3,269,397 shares provides context for the executive's stake in the company. The filing contains no forward guidance, performance conditions beyond continued service, or cash consideration for the award.

Corporate Governance Expert

TL;DR: Grant is a typical service-based RSU award; disclosure is routine under Section 16 filing requirements.

The disclosure clearly states the grant structure: RSUs convertible one-for-one into shares, with 50% vesting on August 14, 2027 and 50% on August 14, 2028, subject to continued service. The Form 4 indicates the issuer, reporting person roles (Director and President and CEO), and the post-grant beneficial ownership. There are no additional conditions, clawbacks, or performance metrics disclosed in this filing. The document fulfills required insider reporting without presenting other governance-related details.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		A(1)		1,587,614	A	$0	3,269,397	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 50% on August 14, 2027, with the remaining 50% vesting on August 14, 2028, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

	/s/ Douglas Carr, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.